ObjectiveOpportunistic fungal infections byCandidaspecies arise among cancer patients due to the weakened immune system following extensive chemotherapy. Prophylaxis with antifungal agents have developed the resistance ofCandidaspp. to antifungals. Accurate identification of yeasts and susceptibility patterns are main concerns that can directly effect on the treatment of patients.MethodsOver a period of three years, 325 cancer patients suspected toCandidainfections were included in the current investigation. The clinical isolates were molecularly identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). All strains, were examined forin vitrosusceptibility to the amphotericin B, itraconazole, fluconazole, and anidulafungin according to the CLSI M27 document.ResultsSeventy-four cancer patients hadCandidainfections (22.7%).Candida albicanswas the most common species (83.8%). Antifungal susceptibility results indicated that 100% of theCandidaisolates were sensitive to amphotericin B; however, 17.6%, 9.4%, and 5.4% of clinical isolates were resistant to anidulafungin, fluconazole, and itraconazole, respectively.ConclusionThe findings of the present work shows a warning increase in resistance to echinocandins. Since all fluconazole resistance isolates were obtained from candidemia, we recommend amphotericin B as the first line therapy for this potentially fatal infection.